5-HT1A Receptor Protein
Introduction
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">5-HT1A Receptor Protein</th>
</tr>
<tr>
<td class="label">Ligand Type</td>
<td>Examples</td>
</tr>
<tr>
<td class="label">Full agonists</td>
<td>8-OH-DPAT, flesinoxan</td>
</tr>
<tr>
<td class="label">Partial agonists</td>
<td>Buspirone, tandospirone</td>
</tr>
<tr>
<td class="label">Antagonists</td>
<td>WAY-100635, p-MPPI</td>
</tr>
<tr>
<td class="label">Inverse agonists</td>
<td>NAD-299</td>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">[Hippocampus](/brain-regions/hippocampus)</td>
<td>Very High</td>
</tr>
<tr>
<td class="label">Septal Nuclei</td>
<td>High</td>
</tr>
<tr>
<td class="label">Amygdala</td>
<td>High</td>
</tr>
<tr>
<td class="label">[Cortex](/brain-regions/cortex)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Hypothalamus</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Raphe Nuclei</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Brainstem</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">MAPK/ERK</td>
<td>Activation</td>
</tr>
<tr>
<td class="label">PI3K/AKT</td>
<td>Activation</td>
</tr>
<tr>
<td class="label">PLCβ</td>
<td>Activation</td>
</tr>
<tr>
<td class="label">β-arrestin</td>
<td>Recruitment</td>
</tr>
<tr>
<td class="label">Condition</td>
<td>Role</td>
</tr>
<tr>
<td class="label">Schizophrenia</td>
<td>Cognitive deficits</td>
</tr>
<tr>
<td class="label">Bipolar disorder</td>
<td>Mood stabilization</td>
</tr>
<tr>
<td class="label">Migraine</td>
<td>Trigeminal nociception</td>
</tr>
<tr>
<td class="label">Eating disorders</td>
<td>Appetite regulation</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Approval</td>
</tr>
<tr>
<td class="label">Buspirone</td>
<td>1986</td>
</tr>
<tr>
<td class="label">Tandospirone</td>
<td>Japan</td>
</tr>
<tr>
<td class="label">Vilazodone</td>
<td>2011</td>
</tr>
<tr>
<td class="label">Vortioxetine</td>
<td>2013</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Flesinoxan</td>
<td>Various</td>
</tr>
<tr>
<td class="label">NLX-101</td>
<td>Neurolixis</td>
</tr>
<tr>
<td class="label">AD-006</td>
<td>Adamed</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/depression" style="color:#ef9a9a">Depression</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">19 edges</a></td>
</tr>
</table>
5 Ht1A Receptor Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
5-HT1A receptor (HTR1A) is a Gi/o protein-coupled serotonin receptor that inhibits adenylate cyclase, reducing intracellular cAMP levels. This receptor is one of the most extensively studied serotonin receptors due to its critical roles in mood regulation, anxiety, cognition, and neuroprotection. HTR1A is highly expressed in brain regions involved in emotional processing and is the target of many anxiolytic and antidepressant drugs. Dysregulation of 5-HT1A signaling is implicated in major depressive disorder, anxiety disorders, schizophrenia, Alzheimer's disease, and Parkinson's disease.
Structure and Pharmacology
Receptor Architecture
5-HT1A is a typical GPCR with seven transmembrane domains:
- N-terminal extracellular domain: Short, unglycosylated
- Seven transmembrane helices (TM1-TM7): Form ligand-binding pocket
- Three intracellular loops: Couple to Gi/o proteins
- C-terminal tail: Contains serine/threonine residues for phosphorylation
Ligand Binding
Structural Features
Key structural elements:
- Conserved DRY motif: Required for G-protein coupling
- Disulfide bond (C98-C178): Stabilizes TM3-EL2
- Ser/Thr phosphorylation sites: Mediate desensitization
- Palmitoylation site (C417): Membrane anchoring
Expression Pattern
Brain Distribution
5-HT1A shows widespread but region-specific expression:
Cellular Localization
- Postsynaptic [neurons](/entities/neurons): Major location in target regions
- Presynaptic terminals: Modulates serotonin release (autoreceptor)
- Glial cells: Astrocyte expression reported
- Dendritic shafts: High density on [dendritic spines](/cell-types/dendritic-spines)
Signaling Mechanisms
Primary Signaling Pathway
HTR1A activates Gi/o proteins leading to:
Inhibition of adenylate cyclase → ↓ cAMP
Activation of GIRK channels → Hyperpolarization
Inhibition of voltage-gated calcium channels → ↓ Ca2+ influx
β-arrestin recruitment → Desensitization and signalingSecondary Signaling Pathways
Electrophysiological Effects
5-HT1A activation produces:
- Membrane hyperpolarization: Via GIRK channel activation
- Reduced neuronal firing: Lower action potential frequency
- Decreased neurotransmitter release: Presynaptic inhibition
- Long-term depression: Synaptic plasticity effects
Disease Associations
Depression
HTR1A is central to antidepressant therapy:
- Mechanism: 5-HT1A partial agonists (buspirone) have anxiolytic effects
- SSRIs effect: Chronic SSRI treatment desensitizes 5-HT1A autoreceptors
- Delayed onset: Time required for autoreceptor desensitization
- Treatment resistance: 5-HT1A dysfunction may contribute
Anxiety Disorders
5-HT1A modulation is therapeutic:
- Generalized anxiety: Buspirone efficacy
- Panic disorder: 5-HT1A agonism reduces panic attacks
- Social anxiety: Investigational therapies
- Post-traumatic stress: Research ongoing
Alzheimer's Disease
5-HT1A involvement in AD:
- Neuroprotection: 5-HT1A activation protects against [Aβ](/proteins/amyloid-beta) toxicity
- Cognitive function: Hippocampal 5-HT1A modulates memory
- Cholinergic interaction: 5-HT1A-[ACh](/entities/acetylcholine) interaction in cognition
- Therapeutic potential: 5-HT1A agonists under investigation
Parkinson's Disease
5-HT1A in PD pathophysiology:
- Motor side effects: 5-HT1A agonism reduces L-DOPA-induced dyskinesias
- Neuroprotection: 5-HT1A activation may protect dopaminergic neurons
- Non-motor symptoms: Depression and anxiety in PD
- Therapeutic target: 5-HT1A modulators for dyskinesias
Other Neurological Conditions
Therapeutic Targeting
FDA-Approved Drugs
Investigational Therapies
Challenges in Drug Development
Central vs peripheral selectivity: Limiting side effects
Autoreceptor vs postsynaptic selectivity: Therapeutic window
Partial agonism: Achieving optimal efficacy
[Blood-brain barrier](/entities/blood-brain-barrier) penetration: Required for CNS effectsAnimal Models
Knockout Studies
- Htr1a-/- mice: Increased anxiety-like behavior
- Conditional KO: Region-specific deletion
- Humanized mice: Express human HTR1A
Phenotypic Findings
- Enhanced stress response
- Impaired emotional regulation
- Altered antidepressant response
- Modified pain perception
Disease Models
- Chronic mild stress: 5-HT1A modulation reverses effects
- Aβ models: 5-HT1A agonists protect
- PD models: 5-HT1A modulation affects dyskinesias
Research Directions
Cryo-EM structure: Understanding ligand recognition
Circuit-specific targeting: Optogenetic approaches
Biomarkers: 5-HT1A imaging in disease
Combination therapies: 5-HT1A + other targets
Personalized medicine: PharmacogenomicsBackground
The study of 5 Ht1A Receptor Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[1]: https://pubmed.ncbi.nlm.nih.gov/10629201/ PMID: 10629201(https://pubmed.ncbi.nlm.nih.gov/10629201/) - 5-HT1A receptor overview
[2]: https://pubmed.ncbi.nlm.nih.gov/10816402/ PMID: 10816402(https://pubmed.ncbi.nlm.nih.gov/10816402/) - Brain distribution
[3]: https://pubmed.ncbi.nlm.nih.gov/15604288/ PMID: 15604288(https://pubmed.ncbi.nlm.nih.gov/15604288/) - Signaling mechanisms
[4]: https://pubmed.ncbi.nlm.nih.gov/17585956/ PMID: 17585956(https://pubmed.ncbi.nlm.nih.gov/17585956/) - Depression treatment
[5]: https://pubmed.ncbi.nlm.nih.gov/19029120/ PMID: 19029120(https://pubmed.ncbi.nlm.nih.gov/19029120/) - Anxiety disorders
[6]: https://pubmed.ncbi.nlm.nih.gov/20139464/ PMID: 20139464(https://pubmed.ncbi.nlm.nih.gov/20139464/) - Alzheimer's disease
[7]: https://pubmed.ncbi.nlm.nih.gov/23452928/ PMID: 23452928(https://pubmed.ncbi.nlm.nih.gov/23452928/) - Parkinson's disease
[8]: https://pubmed.ncbi.nlm.nih.gov/25872154/ PMID: 25872154(https://pubmed.ncbi.nlm.nih.gov/25872154/) - Therapeutic targeting
See Also
- [HTR1A Gene](/genes/htr1a)
- [Serotonin Receptors](/mechanisms/dopaminergic-neuron-vulnerability)
- [Depression](/diseases/depression)
- [Anxiety Disorders](/diseases/anxiety-disorders)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [G](/mechanisms/dopaminergic-neuron-vulnerability)
- [Serotonin Syndrome](/mechanisms/dopaminergic-neuron-vulnerability)
- [Hippocampus](/brain-regions/hippocampus)
External Links
- [UniProt: HTR1A](https://www.uniprot.org/uniprot/P08908)
- [PDB: 5-HT1A Receptor](https://www.rcsb.org/structure/7E2Z)
- [GeneCards: HTR1A](https://www.genecards.org/cgi-bin/carddisp.pl?gene=HTR1A)
- [OMIM: HTR1A](https://www.omim.org/entry/109710)
- [IUPHAR: 5-HT1A Receptor](https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2)